Patents Examined by Sagar Patel
  • Hydrosoluble compounds derived from benzimidazole used in treating fasciolosis
    Patent number: 10239842
    Abstract: The present invention relates to hydrosoluble compounds derived from benzimidazole represented by general formula I: wherein: Y1 e Y2 are independently O or S, and at least one of Y1 and Y2 is O; R1 and R2 are independently hydrogen or a cation, both are hydrogen or both are cations; R3 is a C1-4 alkyl; R4 and R5 are independently halogen or a —OR6 alkoxide; R6 is C6-C10 aryl linked in 5- or 6-position of benzimidazole nucleus.
    Type: Grant
    Filed: November 25, 2015
    Date of Patent: March 26, 2019
    Assignee: UNIVERSIDAD NACIONAL AUTONOMA DE MEXICO
    Inventors: Rafael Castillo Bocanegra, Miguel Angel Flores Ramos, Maria Alicia Hernandez Campos, Osvaldo Froylan Ibarra Velarde, Remedios Yolanda Vera Montenegro
  • CDK2/4/6 inhibitors
    Patent number: 10233188
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: March 19, 2019
    Assignee: Pfizer Inc.
    Inventors: Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Asako Nagata, Sacha Ninkovic
  • 3-oxo-3-(arylamino)propanoates, a process for their preparation, and their use in preparing pyrrolidinones
    Patent number: 10227286
    Abstract: Disclosed are compounds of Formula I, including all stereoisomers and salts thereof, wherein Q1, Q2 and R are as defined in the disclosure. Also disclosed is a method for preparing a compound of Formula I, comprising contacting a compound of Formula II with a compound of Formula III optionally in the presence of a catalyst or a base to form a compound of Formula I. Further disclosed is a method for preparing a compound of Formula IV, comprising reductively cyclizing a compound of Formula I in the presence of a reducing agent.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: March 12, 2019
    Assignee: FMC Corporation
    Inventor: Andrew Duncan Satterfield
  • Cystathionine-gamma-lyase (CSE) inhibitors
    Patent number: 10227314
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds which inhibit cystathionine-?-lyase (CSE). Also described herein are methods for using such CSE inhibitors, alone or in combination with other compounds, for treating diseases or conditions that would benefit from CSE inhibition.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: March 12, 2019
    Assignee: SOVA PHARMACEUTICALS, INC.
    Inventors: Sergio G. Durón, Justin Chapman, Simon G. Sydserff, Srinivas G. Rao, Gregory Stein
  • Method of inhibiting cancer cell, method for detecting cancer cell, and system for detecting cancer cell
    Patent number: 10220024
    Abstract: An object of the present invention is to provide a cancer cell inhibitory drug, particularly a cancer stem-cell inhibitory drug, or a cancer stem-cell detection probe. A cancer cell inhibitory drug containing at least a compound represented by general formula (1).
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: March 5, 2019
    Assignee: CANON KABUSHIKI KAISHA
    Inventors: Taichi Shintou, Tsuyoshi Nomoto, Kohei Watanabe, Takeshi Miyazaki, Toshio Tanaka, Yasuhito Shimada, Yuhei Nishimura
  • Mono- or di-substituted indoles as dengue viral replication inhibitors
    Patent number: 10206902
    Abstract: The present invention concerns mono- or di-substituted indole compounds of formula (I) which are useful to prevent or treat dengue viral infections and also relates to said compounds for use as a medicine, more preferably for use as a medicine to treat or prevent dengue viral infections. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the compounds, to the compositions or preparations for use as a medicine, more preferably for the prevention or treatment of dengue viral infections. The invention also relates to processes for preparation of the compounds.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: February 19, 2019
    Assignees: Janssen Pharmaceuticals, Inc., Katholieke Universiteit Leuven
    Inventors: Bart Rudolf Romanie Kesteleyn, Jean-François Bonfanti, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Dorothée Alice Marie-Eve Bardiot, Arnaud Didier M Marchand
  • Benzathine analogs
    Patent number: 10159674
    Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X is a divalent linking moiety; and R1-R10 are each individually H, optionally-substituted alkyl, optionally-substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, halogen, amino, or hydroxy, provided that at least one of R3 or R8 is an optionally-substituted alkyl, a substituted alkoxy, optionally-substituted aryl, optionally-substituted cycloalkyl, optionally-substituted heterocyclic, or halogen.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: December 25, 2018
    Assignees: University of Pittsburgh—Of the Commonwealth System of Higher Education, The United States of America as represented by the Department of Veterans Affairs
    Inventors: Beibei Chen, Rama K. Mallampalli
  • Nitrogen-containing saturated heterocyclic compound
    Patent number: 10155731
    Abstract: The present invention provides a nitrogen-containing saturated heterocyclic compound of the formula [I]: wherein R1 is a cycloalkyl group and the like, R22 is an optionally substituted aryl and the like, R is a lower alkyl and the like, T is a carbonyl group, Z is —O— and the like, and R3 to R6 are the same or different and a hydrogen atom and the like; or a pharmaceutically acceptable salt, that is useful as a renin inhibitor.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: December 18, 2018
    Assignees: MITSUBISHI TANABE PHARMA CORPORATION, SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.
    Inventors: Toru Iijima, Hiroshi Sugama, Takayuki Kawaguchi, Jingkang Shen, Guangxin Xia, Jianshu Xie, Miki Hirai
  • Compound for organic electric element, organic electric element comprising the same and electronic device thereof
    Patent number: 10141516
    Abstract: Provides herein are a compound capable of improving light emitting efficiency, stability, and lifespan of the element, an organic element using the same, and an electric device for the same.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: November 27, 2018
    Assignee: DUK SAN NEOLUX CO., LTD.
    Inventors: Bumsung Lee, Yeonhee Choi, Daesung Kim, Soungyun Mun, Jungcheol Park, Kiho So, Jinho Yun, Daehwan Oh, Seungwon Yeo
  • Method for producing kakeromycin and derivatives thereof
    Patent number: 10106509
    Abstract: Provided is a production method of kakeromycin and a derivative thereof showing an antifungal activity and cytotoxicity and expected as a new antifungal agent or anticancer agent, by chemical synthesis. A production method of a compound represented by the formula (1): wherein R is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; and n is 0 or 1, or a salt thereof, including a step of subjecting a compound represented by the formula (2): wherein R and n are as defined above, or a salt thereof, to an oxidation reaction.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 23, 2018
    Assignees: OP BIO FACTORY CO., LTD., SEED RESEARCH INSTITUTE CO., LTD.
    Inventors: Teruhiko Ishikawa, Morita Iwami
  • Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
    Patent number: 10100043
    Abstract: Provided are cycloalkyl- and cycloalkenyl-substituted benzaldehydes and heteroaldehydes of formula (I) that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions containing the modulators, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 16, 2018
    Assignees: Global Blood Therapeutics, Inc., Cytokinetics, Inc.
    Inventors: Brian Metcalf, Chihyuan Chuang, Zhe Li
  • Asymmetric synthesis of funapide
    Patent number: 10100060
    Abstract: This invention is directed to asymmetric synthesis of funapide, which is useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: October 16, 2018
    Assignee: Xenon Pharmaceuticals Inc.
    Inventors: Ronen Ben-David, Jian Chen, Michael A. Christie, Mina Gadelrab Dimitri, Graciela Noemi Gershon, Linli He, Nelson G. Landmesser, Daniel V. Levy, Orel Yosef Mizrahi, Partha S. Mudipalli, Harlan F. Reese, Joseph A. Sclafani, Yi Wang
  • Competitive PPAR-gamma antagonists
    Patent number: 10093628
    Abstract: The present invention pertains to a new compound E)-2-(5-((4-methoxy-2-(trifluoromethyl)quinolin-6-yl)methoxy)-2-((4-(trifluoromethyl) benzyl)oxy)-benzylidene) hexanoic acid (MTTB), and its derivatives. The compounds of the invention are useful as selective peroxisome proliferator-activated receptor gamma (PPAR?) antagonists and are indicated for the use in the treatment of immune related diseases such as systemic inflammation, sepsis and septic shock.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: October 9, 2018
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Tilo Knape, Andreas Von Knethen, Michael John Parnham, Manfred Schubert-Zsilavecz, Mario Wurglics, Daniel Flesch
  • 4-oxo-N-(4-hydroxyphenyl)retinamide derivatives as therapeutic agents for the treatment of cancer
    Patent number: 10093621
    Abstract: The present invention relates to a compound having formula (I) below or a pharmaceutically acceptable salt thereof: wherein: X is —COOH or NH2; R is a straight or branched C1-C10 alkylene chain; and R1 is H, straight or branched C1-C10 alkyl, aryl, or R2CO— wherein R2 is straight or branched C1-C10 alkyl, for use as antitumoral agents.
    Type: Grant
    Filed: September 16, 2015
    Date of Patent: October 9, 2018
    Assignee: FONDAZIONE IRCCS INSTITUTO NAZIONALE DEI TUMORI
    Inventors: Maria Grazia Daidone, Valentina Appierto, Paola Tiberio, Sabrina Dallavalle, Loana Musso, Elisa Niccolini
  • Bifunctional cytotoxic agents
    Patent number: 10086085
    Abstract: Cytotoxic dimers comprising CBI-based and/or CPI-based sub-units, antibody drug conjugates comprising such dimers, and to methods for using the same to treat cancer and other conditions.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: October 2, 2018
    Assignee: Pfizer Inc.
    Inventors: Andreas Maderna, Matthew David Doroski, Zecheng Chen, Hud Lawrence Risley, Jeffrey Michael Casavant, Christopher John O'Donnell, Alexander M. Porte, Chakrapani Subramanyam
  • Sortilin binding compounds, formulations, and uses thereof
    Patent number: 10085969
    Abstract: Provided herein are compounds and formulations thereof that can be capable of binding to sortilin or an analog thereof. Also provided herein are methods of administering the compounds and formulation provided herein to a subject in need thereof.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: October 2, 2018
    Assignees: University of South Florida, University of Rochester
    Inventors: Robert Pleasants Sparks, Wayne Charles Guida, Janet Lindsay DeHoff-Sparks
  • Radioactive fluorine labeling precursor compound and method for manufacturing radioactive fluorine labeled compound using the same
    Patent number: 10081620
    Abstract: There is provided a labeling precursor compound represented by the following general formula (2): wherein R1 represents an alkynyl group, an alkynyloxy group, an azide group, an azidoalkyl group, an arylazide group, a monocyclic or condensed polycyclic aryl group or a nitrogen-containing heterocycle; R2 and R3 each independently represent an alkyl group or a hydroxyalkyl group which hydroxy group may be protected with a protecting group, and n is an integer of 1 or 2; R6 represents an alkyl group or —CONR11R12 wherein R11 and R12 each independently represent an alkyl group or a monocyclic or condensed polycyclic aryl group; and R4, R5, R7 and R8 each independently represent a hydrogen atom, an alkyl group or an alkoxy group.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: September 25, 2018
    Assignees: NIHON MEDI-PHYSICS CO., LTD., TOKYO INSTITUTE OF TECHNOLOGY
    Inventors: Masahito Toyama, Masato Kiriu, Hiroshi Tanaka
  • Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants
    Patent number: 10065926
    Abstract: The invention relates to the use of substituted dihydrooxindolylsulfonamides or salts thereof of the formula (I) where the radicals in the general formula (I) correspond to the definitions given in the description, for enhancing stress tolerance in plants to abiotic stress, and/or for increasing plant yield.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: September 4, 2018
    Assignee: BAYER CROPSCIENCE AKTIENGESELLSCHAFT
    Inventors: Jens Frackenpohl, Guido Bojack, Hendrik Helmke, Stefan Lehr, Thomas Mueller, Lothar Willms, Jan Dittgen, Dirk Schmutzler, Udo Bickers, Harry Strek, Rachel Baltz
  • Amorphous Tecovirimat preparation
    Patent number: 10045963
    Abstract: Disclosed are methods for the preparation of amorphous N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus. Also disclosed are methods for the preparation of amorphous solid dispersion of N-[(3aR,4R,4aR,5aS,6S,6aS)-3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl]-4-(trifluoromethyl)-benzamide.
    Type: Grant
    Filed: January 2, 2018
    Date of Patent: August 14, 2018
    Assignee: SIGA TECHNOLOGIES, INC.
    Inventors: Shanthakumar R. Tyavanagimatt, N K Peter Samuel, Joseph Paz, Ying Tan, Dennis E. Hruby
  • Pyrazolyl carboxylic acid and pyrazolyl urea derivative compounds
    Patent number: 10035774
    Abstract: Pyrazolyl carboxylic acid and pyrazolyl urea derivatives have been synthesized, which are useful in the manufacture of cephalosporin antibiotic compounds.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 31, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kristos Adrian Moshos, Valdas Jurkauskas, Yisheng Yang, Youchu Wang